We started commercial sales activity of the ArtVentive EOS™ in April 2016. From the very beginning, ArtVentive adopted a focused approach to the sales process, development and continuous growth. In the European markets, we market and sell our products through industry distributors. In the U.S, we market directly to selected University Hospitals and private clinics constantly expanding of customer base. We have targeted sales and marketing efforts to interventional radiologists and vascular surgeons with experience using similar catheter-based procedures, such as angioplasty and stenting. Peer-to-peer education is also a key element of our sales strategy.
Our progress to date has been significant where we have achieved 400 – 500% sales growth per quarter. Management is very confident in the sales development and our company’s expansion based on natural organic growth.
ArtVentive EOS™ Device featured at SIR 2017 Conference
Visit us at booth #560.
ArtVentive Medical Group, Inc. (“ArtVentive”) announced today its strategic sales plan for the company’s growth and highlighted recent commercialization progress in the United States and Europe.
Dr, Leon Rudakov, ArtVentive’s founder and Chief Technology Officer, and Bill Olson, newly appointed Chief Executive Officer, identified an innovative sales and marketing strategy for ArtVentive’s revolutionary blood vessel occlusion device EOS™.
ArtVentive Launches U.S. commercialization by Showcasing its EOS™ Device at GEST-2016. May 2016, New York
ArtVentive Medical Group, Inc. commenced the launch of its flagship occlusion device product, the ArtVentive Endoluminal Occlusion System (EOS™) at the Global Embolization Symposium and Technologies (GEST) in New York, NY on May 5-8. The introduction in the United States follows the initial commercialization in the E.U. last year.